CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.27BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
140.04%vs all stocks
Market Capitalization
1.27BUSDvs all stocks (USD)
Enterprise Value
700.41MUSDvs all stocks (USD)
Forward P/E
-9.15xvs Biotechnology peers
Price to Book (MRQ)
3.47xvs Biotechnology peers
Enterprise to EBITDA
-6.17xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-36.43%vs Biotechnology peers
Return on Equity (TTM)
-38.32%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-95.10MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-100.01MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-127.41MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-113.54MUSDvs all stocks (USD)
Pre-tax Income
-127.35MUSDFY2025 · Dec 31, 2025Income Tax Expense
58.00KUSDFY2025 · Dec 31, 2025Net Income
-127.41MUSDFY2025 · Dec 31, 2025EBIT
-113.54MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-113.52MUSDFY2025 · Dec 31, 2025Research & Development
93.12MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
20.42MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
7.78MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-127.41MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-85.34MUSDFY2025 · Dec 31, 2025Free Cash Flow
-85.54MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
88.44MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-127.41MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
26.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
20.01MUSDFY2025 · Dec 31, 2025Other Non-cash Items
21.67MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
361.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
2.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-196.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-261.19MUSDFY2025 · Dec 31, 2025Sale of Investments
14.41MUSDFY2025 · Dec 31, 2025Other Investing Activity
-31.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-247.01MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
171.27MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
360.38MUSDFY2025 · Dec 31, 2025Shares Outstanding
49.35MSharesUpdated Jul 19, 2026Float Shares
39.69MSharesUpdated Jul 19, 2026Shares Short
8.15MSharesUpdated Jul 19, 2026Short Ratio
4.89daysvs all stocks
Short % of Shares Outstanding
16.55%vs all stocks
% Held by Insiders
0.83%vs all stocks
% Held by Institutions
88.14%vs all stocks
Total Cash (MRQ)
311.30MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.31USDUpdated Jul 19, 2026Total Debt (MRQ)
808.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0027xvs Biotechnology peers
Current Ratio (MRQ)
14.29xvs Biotechnology peers
Book Value per Share (MRQ)
6.01USDUpdated Jul 19, 2026Total Assets
349.78MUSDvs all stocks (USD)
Total Current Assets
348.82MUSDFY2025 · Dec 31, 2025Total Liabilities
17.26MUSDFY2025 · Dec 31, 2025Total Non-current Assets
965.00KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
724.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
16.54MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
88.44MUSDFY2025 · Dec 31, 2025Other Short-term Investments
247.72MUSDFY2025 · Dec 31, 2025Accounts Payable
2.15MUSDFY2025 · Dec 31, 2025Long-term Debt
724.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-174.39MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
332.52MUSDvs all stocks (USD)
52-Week Low
6.67USDUpdated Jul 19, 202652-Week High
28.00USDUpdated Jul 19, 202652-Week Change
140.04%vs all stocks
50-Day MA
20.83USDUpdated Jul 19, 2026200-Day MA
15.91USDUpdated Jul 19, 2026Avg 10-Day Volume
1.06MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.45MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.63USDUpdated Jul 19, 2026Other Income / Expense
-21.59MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $1.27B, above the global median of $1.15BNotable
Market cap (USD): 1,269,536,992Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Tianjin Ringpu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bio-Thera Solutions Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sonoscape Medical Corp.
Tier 1ProductionApproval-Gated PipelineRule
Liaoning Chengda Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Inhibrx Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ardelyx Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sinonep-Allsino Bio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Corvus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Celltrion Pharm, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Hisun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai Geoharbour Construction Group Co. Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Sung Kwang Bend Co. Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
EO Technics Co., Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated